Summary A separate filing for the drug in Europe is progressing on schedule.
LONDON (Reuters) - U.S. regulators have pushed back an approval decision on GlaxoSmithKline s experimental diabetes drug albiglutide by three months until April 15, 2014, Britain s biggest drugmaker said on Friday.
A separate filing for the drug in Europe is progressing on schedule.
The once-weekly treatment for type 2 diabetes belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca.
Based on reported clinical trial results, industry analysts have questioned how well albiglutide will fare in a crowded market - especially with a promising new rival in the pipeline in the form of Eli Lilly s dulaglutide.
